179 related articles for article (PubMed ID: 38604895)
1. Effect of SGLT2 inhibitors on anemia and their possible clinical implications.
Cases A; Cigarrán S; Luis Górriz J; Nuñez J
Nefrologia (Engl Ed); 2024; 44(2):165-172. PubMed ID: 38604895
[TBL] [Abstract][Full Text] [Related]
2. Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes.
Marathias KP; Lambadiari VA; Markakis KP; Vlahakos VD; Bacharaki D; Raptis AE; Dimitriadis GD; Vlahakos DV
Am J Nephrol; 2020; 51(5):349-356. PubMed ID: 32241009
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia.
Packer M
Am J Nephrol; 2024; 55(2):255-259. PubMed ID: 37231827
[TBL] [Abstract][Full Text] [Related]
4. Increase in hematocrit with SGLT-2 inhibitors - Hemoconcentration from diuresis or increased erythropoiesis after amelioration of hypoxia?
Ekanayake P; Mudaliar S
Diabetes Metab Syndr; 2023 Feb; 17(2):102702. PubMed ID: 36657305
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease.
Maruyama T; Takashima H; Oguma H; Nakamura Y; Ohno M; Utsunomiya K; Furukawa T; Tei R; Abe M
Diabetes Technol Ther; 2019 Dec; 21(12):713-720. PubMed ID: 31385724
[No Abstract] [Full Text] [Related]
6. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
[TBL] [Abstract][Full Text] [Related]
7. The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.
Brown E; Wilding JPH; Alam U; Barber TM; Karalliedde J; Cuthbertson DJ
Ann Med; 2021 Dec; 53(1):2072-2089. PubMed ID: 33107349
[TBL] [Abstract][Full Text] [Related]
8. Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.
Verma S; Mudaliar S; Greasley PJ
Adv Ther; 2024 Jan; 41(1):92-112. PubMed ID: 37943443
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
10. Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotransporter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects.
Sano M; Goto S
Circulation; 2019 Apr; 139(17):1985-1987. PubMed ID: 31009585
[No Abstract] [Full Text] [Related]
11. Roles for SGLT2 Inhibitors in Cardiorenal Disease.
Green JB; McCullough PA
Cardiorenal Med; 2022; 12(3):81-93. PubMed ID: 35835083
[TBL] [Abstract][Full Text] [Related]
12. Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
Qiu M; Ding LL; Zhan ZL; Zhou HR
Eur J Intern Med; 2021 May; 87():98-99. PubMed ID: 33485738
[No Abstract] [Full Text] [Related]
13. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
[TBL] [Abstract][Full Text] [Related]
14. Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease.
Chan JSK; Perone F; Bayatpoor Y; Tse G; Harky A
Expert Opin Pharmacother; 2023 Jun; 24(8):935-945. PubMed ID: 37070470
[TBL] [Abstract][Full Text] [Related]
15. Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD.
Hu JC; Shao SC; Tsai DH; Chuang AT; Liu KH; Lai EC
JAMA Netw Open; 2024 Mar; 7(3):e240946. PubMed ID: 38436955
[TBL] [Abstract][Full Text] [Related]
16. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
O'Meara E; Verma S
Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.
Kelly MS; Lewis J; Huntsberry AM; Dea L; Portillo I
Postgrad Med; 2019 Jan; 131(1):31-42. PubMed ID: 30449220
[TBL] [Abstract][Full Text] [Related]
18. The cardiovascular outcomes, heart failure and kidney disease trials tell that the time to use Sodium Glucose Cotransporter 2 inhibitors is now.
Johansen ME; Argyropoulos C
Clin Cardiol; 2020 Dec; 43(12):1376-1387. PubMed ID: 33165977
[TBL] [Abstract][Full Text] [Related]
19. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
Yang S; Zhao L; Mi Y; He W
Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
[TBL] [Abstract][Full Text] [Related]
20. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E
Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
